posted
Grabbed some about a month ago. Sold most but riding the rest. Outstanding at February 11, 2008 220,035,668 shares
PR from Feb 5th CLX Investment Company CEO Files Form 4 Detailing Acquisition of 5 Million Shares of Common Stock CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today reported that Vera Leonard, chief executive officer of Zonda and CLX, has acquired 5 million shares of CLX common stock, bringing her total common stock position to 10 million shares. The shares were acquired by Ms. Leonard on January 30, 2008 at a price of $0.003 per share.
The 5 million shares were granted to Ms. Leonard as part of her compensation package for accepting the president/CEO position with CLX. Ms. Leonard was initially appointed to the position of president/CEO of Zonda to develop the company and evaluate its medical diagnostic testing products to determine the manner in which they be developed as assets for CLX. Since her appointment, CLX and Zonda have taken definitive steps toward the initiation of clinical trials for Zonda's rapid point of care test for chlamydia, including its work with American Health Partners, Safis Solutions, and Sentry Logistic Solutions. The clinical trials, currently scheduled to begin in the mid- to late- 1st calendar quarter of 2008, are being initiated as part of the process to achieve FDA clearance for the chlamydia testing product.
"Ms. Leonard, in a relatively short time, has prepared Zonda and its chlamydia test for the upcoming scheduled clinical trials, and we are pleased to include this additional share position as part of her compensation package as CEO of CLX," stated Robert McCoy, chairman of CLX Investment Company. "Ms. Leonard has done an excellent job leading both CLX and Zonda thus far, and the Board is highly confident in her ability to deliver value to CLX shareholders. As CLX and its subsidiary operations reach identifiable milestones and achievements, the Board intends to provide additional opportunities for Ms. Leonard to increase her share position as part of her compensation."
Chlamydia is now the most frequently reported bacterial sexually transmitted disease (STD) in the United States, with over 1 million cases of chlamydial infection reported nationwide in 2006. Due to under-reporting, it is estimated that there are approximately 2.8 million new cases of chlamydia in the United States each year. The majority of people with chlamydia are not aware of their infections, and if untreated, chlamydial infections can progress to serious reproductive and other health problems for women, including infertility and an increased likelihood of infection with HIV, if exposed. Yet, chlamydia is easily treated and cured with antibiotics once it is detected. Because chlamydia is largely asymptomatic, detection is the key to stemming the spread of chlamydia in the U.S. and around the world.
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
CLX Investment Company Announces Selection of Contract Research Organization (CRO) for Clinical Trials on Zonda's Rapid Point of Care Test for Chlamydia
Tuesday, March 11 2008 11:40 AM, EST Market Wire "US Press Releases "MURRIETA, CA -- (MARKET WIRE) -- 03/11/08 -- CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated , a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the company has selected Trial Care International, LLC (TCI) to serve as Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia. Trial Care International, LLC (http://trialcareintl.com/index.html) specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry through partnering and long-term relationships with its clients. TCI offers a full range of clinical services specializing in: protocol design, project management, investigator recruitment and selection, document collection and supply shipping, contract and grant administration, investigator meeting coordination and facilitation, monitoring, GCP auditing and regulatory consulting. Safis Solutions assisted with selection of Trial Care International through a process that began with a request for proposal from several CROs. Two finalists were then identified to make detailed presentations, and TCI was ultimately selected. Safis Solutions (www.safis-solutions.com), an Indianapolis -based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX. "We are pleased to have identified Trial Care International as the CRO for Zonda's clinical trials and look forward to their support and expertise. Having the services of a top quality CRO is a crucial element in clinical trial management. This is a big step forward in the process of bringing this important product to the market. We believe Trial Care International is the ideal partner to assist us as we navigate this process," stated Vera Leonard, chief executive officer of Zonda and CLX. Ms. Leonard recently participated in a question and answer feature that has been posted to the CLX website at http://www.clxinvestments.com/othermedia.php, and a link to the interview has also been added to the company's profile on the home page of Equity Digest at www.equitydigest.com. The question and answer feature includes a detailed discussion by Ms. Leonard of the estimated market potential for Zonda's rapid point of care diagnostic test for chlamydia. To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php. About CLX Investment Company CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards. All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance. Contacts: For CLX Investment Company : Gemini Financial Communications A. Beyer 951-677-8073 Email Contact
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
This puppy has been smokin' but has seen resistance at .005. If it can break that, we can see a penny this week. Anybody else out there in or watching this?
-------------------- To fool, we can't get fooled again. Posts: 32 | From: VT | Registered: Mar 2006
| IP: Logged |
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
CLX Investment Company Issues March 2008 Newsletter Reviewing Preparations for Clinical Trials on Zonda's Rapid Point of Care Test for Chlamydia Including Planned Validation Study
posted
People wanted to take their profits while the get'n was good. Those that got in this morning or yesterday saw the selling so they sold for a loss.
Hope you saved your initial investment!
Posts: 858 | Registered: Jul 2005
| IP: Logged |
-------------------- The difference between genius and stupidity is that genius has its limits Posts: 10204 | From: NYC | Registered: Mar 2006
| IP: Logged |
posted
low float, product's on the way, never had been under .002 for more than 3 days, it always bounced back... .005 is really easy
-------------------- i wish one day i would be rich but the wish is all in your hand!! Posts: 239 | From: New Jersy | Registered: Mar 2006
| IP: Logged |
posted
Jumped in this today. Maybe I shouldn't have. What do you guys think. Looked like it was going to go.
Posts: 339 | From: Canada | Registered: Dec 2005
| IP: Logged |
posted
Lots of volume lately, something is up. I'm sure there is some dilution going on, but I also think there is still a good bounce in this one...
Posts: 2741 | From: Seattle | Registered: Feb 2005
| IP: Logged |
CLX Medical, Inc. Announces Letter of Intent for Acquisition of Additional Medical Diagnostic Testing Product CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market.
The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.
The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials.
As CLX supports the Zonda product line, it will continue to identify additional innovative products as potential acquisitions and opportunities for distribution relationships for CLX. CLX intends to acquire, license and distribute innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States.
"The letter of intent is an important milestone in the process of acquiring this targeted product," commented Vera Leonard, chief executive officer of Zonda and CLX. "We look forward to reaching the next steps in the process, including the announcement of the name of the product, so we can begin discussing what we see as the significant market potential for this acquisition."
In addition to the U.S. market, the new acquisition may have tremendous potential in Europe, where the Zonda chlamydia product is sold, and in other overseas markets.
To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.
About CLX Medical, Inc.
CLX Medical, Inc. (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
Contact: Gemini Financial Communications, Inc. A. Beyer 951-677-8073 Email Contact
posted
CLX Medical, Inc. Announces Increasing Interest and Sales of Zonda's Rapid Point of Care Test for Chlamydia European Health Agencies Focus on the Growing Chlamydia Epidemic CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that the company's European distributors have reported an increased interest in diagnostic testing products for chlamydia, which has resulted in increased sales of Zonda Incorporated's rapid point of care test for chlamydia by those distributors.
Distributors in the United Kingdom, Belgium, the Netherlands and Luxemburg have reported the increase over recent months and attribute it to a greater focus on screening for chlamydia by national health organizations in those countries.
The National Chlamydia Screening Programme (NCSP) in the United Kingdom has put an increased focus on the chlamydia epidemic and encourages testing for all sexually active men and women under the age of 25. The program in England was established in 2003 with the objective of controlling chlamydia through the early detection and treatment of asymptomatic infection. As in the United States, chlamydia is now the most commonly reported sexually transmitted infection in the UK.
"Given the growing chlamydia epidemic, it is no surprise that interest in chlamydia screening products, including Zonda's HandiLab-C test for Chlamydia, is increasing in Europe as well as in the United States," commented Vera Leonard, chief executive officer of Zonda and CLX. "Chlamydia is a serious health problem, and we are currently positioning the Zonda chlamydia testing product to serve as an effective and readily available screening rapid point of care device for health care professionals worldwide."
CLX currently holds a majority interest in Zonda, which has developed rapid point of care tests for medical and non-medical markets. Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms and are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets. Zonda's chlamydia product has been distributed in Europe for approximately three years.
CLX is currently preparing to initiate clinical trials for Zonda's HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets. As part of the preparation for clinical trials, a validation study has been commissioned in order to perfect the testing protocol.
The company has also identified and is in negotiations with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market.
The master distributor will provide product support and product packaging control; coordinate sales to other European distributors; distribute products in its own territory; act as the registered EU representative for CE marked products; and assist with the development and implementation of pricing structures.
"Even as we continue through the process of achieving FDA clearance in the United States, we will also work with our selected master distributor to increase the use of the HandiLab-C in the European market," added Ms. Leonard.
To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.
About CLX Medical, Inc.
CLX Medical, Inc. (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc., which has developed rapid point of care tests for medical and non-medical markets, and CLX recently announced a letter of intent to acquire another rapid diagnostic device for the medical market. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
Contact: Gemini Financial Communications, Inc. A. Beyer
Posts: 339 | From: Canada | Registered: Dec 2005
| IP: Logged |
CLXN which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that the first stages of a pre-clinical trials validation study on Zonda Incorporated's rapid point of care test for chlamydia have been initiated and that the testing itself is expected to commence once the required chlamydia cells have been grown and laboratory staff has been properly trained in the study procedures. CLX currently holds a majority interest in Zonda, whose tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms and are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets. Zonda's chlamydia product has been distributed in Europe for approximately three years. The validation study is designed to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product. With FDA clearance, CLX will seek to achieve widespread distribution for the HandiLab-C within the U.S., as well as broader distribution into worldwide markets. IIT Research Institute (IITRI) ( http://www.iitri.org) has been engaged to serve as the laboratory that will conduct a validation study. IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years. IITRI operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago facility. "It is extremely important that a sound proof-of-concept and pre-clinical validation has been conducted prior to initiation of the clinical study, and we are pleased that the training and other preparations are currently underway," stated Vera Leonard, chief executive officer of Zonda and CLX. "The testing itself will occur in a relatively short period, but the work leading up to it is critically important, both for the study and for the clinical trials expected to be initiated afterwards." "We look forward to receiving feedback from the validation study, which we expect to be completed by mid-June," Ms. Leonard added.
Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
posted
CLX Medical, Inc. Announces Results of Meetings at AACC Annual Meeting and Clinical Lab Expo Thursday 08/07/2008 9:45 AM ET - Market Wire
Related Companies Symbol Last %Chg CLXN 0.0007 75.00%
As of 10:40 AM ET 8/7/08 CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today updated shareholders on its successful attendance at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo held last week at in Washington, DC.
Among the more significant accomplishments achieved by CLX Medical management at the event was reaching agreement with a major European distributor to serve as the sole importer of CLX's subsidiary products into the European market. In the meetings with the targeted master distributor, a marketing strategy for European sales was established, and CLX expects to announce a Letter of Intent with the distributor in the next several days. The name of the company will also be announced at that time.
CLX Medical also met with the current owner and the manufacturer of an additional medical diagnostic testing product, which CLX expects to acquire in the near term. The two companies have reached agreement on acquisition terms and on a timeline for definitive agreement and the close of the acquisition. CLX expects to identify the product, the market opportunity presented by this acquisition and details of its launch plan within the next two weeks.
The AACC event was held from July 27-31 at the Walter E. Washington Convention Center in Washington, DC. AACC's Clinical Lab Expo, the largest gathering of laboratory industry companies in the world, was anticipated to include 1,800 booths and 650 exhibitors. The Expo allows visitors to see and speak to world-leading companies about the latest developments in laboratory medicine. More information on the event can be found at http://www.aacc.org/EVENTS/ANN_MEET/Pages/default.aspx.
"Everything we had hoped to accomplish at the AACC Annual Meeting and Clinical Lab Expo was achieved, and we look forward to providing the details of our agreement with our master distributor for Europe in the next several days and of our anticipated acquisition target shortly thereafter," commented Vera Leonard, chief executive officer of CLX Medical. "Our attendance at the event was more than worth the time we spent there, and we hope that CLX shareholders will follow our new releases closely as we follow-up with the details of each of these agreements."
To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.
About CLX Medical, Inc.
CLX Medical, Inc. (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc., which has developed rapid point of care tests for medical and non-medical markets, and CLX recently announced a letter of intent to acquire another rapid diagnostic device for the medical market. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical's control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
Contact: Gemini Financial Communications, Inc. A. Beyer 951-677-8073 Email Contact
-------------------- Please do your DD. Break some bread with me! Posts: 1138 | From: atlanta | Registered: Apr 2006
| IP: Logged |
CLX Medical, Inc. (OTCBB: CLXN), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced that the company has entered into a letter of intent with ThyroTec, LLC to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX will now proceed toward a definitive agreement for the acquisition of ThyroTest, which would be positioned in a wholly owned subsidiary of CLX Medical.
The last phase of CLX's analysis and research process on the ThyroTest® product includes an in-depth analysis of competitive strengths and is part of an ongoing study of the product by a clinical laboratory affiliated with a major U.S. university. Data from the study is expected to be made available in the near term.
In addition to the acquisition of ThyroTest®, CLX Medical expects to enter into a co-development deal with ThyroTec, LLC to secure worldwide sales and marketing rights for 2 additional products in the medical diagnostic testing market.
"Our analysis of the potential market for ThyroTest indicates that it is much larger than the current estimated instance of hypothyroidism in the U.S.," stated Vera Leonard, chief executive officer of CLX Medical. "The wide range of symptoms, most of them very common in today's society, opens what we view to be a significant opportunity for a screening device like ThyroTest® that is CLIA waived and therefore allowed to be used in a wide variety of testing venues. We also believe that ThyroTest® is significantly superior to competitive products, and our marketing strategy for the product will include providing data that supports this contention."
CLX anticipates that Ms. Leonard will be providing additional follow-up information on ThyroTest®, as well as the opportunity presented by this product and the acquisition in the coming days.
To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
posted
Company's handilab trial result goes caput! things dont seem to be going right for this one at this moment.....however, at .0001...I might play it like a lotto ticket..just wont throw too much at it. JMO
-------------------- Please do your DD. Break some bread with me! Posts: 1138 | From: atlanta | Registered: Apr 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
